Orchasp Limited announced the outcome of its Board Meeting held on February 10, 2026, where directors approved unaudited financial results for Q3FY26 and made significant board appointments. The company submitted comprehensive regulatory filings to BSE and NSE under SEBI (LODR) Regulations, 2015.

Financial Performance Overview

The company's Q3FY26 financial results showed mixed performance compared to the previous year. Net profit declined to Rs. 19.03 lakhs from Rs. 50.10 lakhs in Q3FY25, while revenue from operations decreased significantly.

Nine-Month Performance Turnaround

Despite quarterly challenges, the nine-month performance demonstrated remarkable recovery. The company achieved net profit of Rs. 94.02 lakhs compared to a substantial loss of Rs. 1,354.63 lakhs in the corresponding period of the previous year.

Board Appointments and Restructuring

The Board approved two key appointments effective February 10, 2026. Mr. Srinivasu Sunkara (DIN: 11509166) was appointed as Independent Director for five years (February 10, 2026 to February 9, 2031). He brings 21 years of global experience in digital technology leadership across healthcare, retail, supply chain, and financial domains, holding a Master's degree in Computer Science and Ph.D. in Data Mining from Andhra University.

Ms. Sirisha Pattapurathi was appointed as non-executive non-independent woman director. She holds an MBA in Technology Management from The University of Sheffield, UK, with 19 years of experience in finance, vendor operations, and supplier management at Microsoft. She is the sister of Mr. Chandra Sekhar Pattapurathi, the company's Managing Director and CFO.

Independent Directors' Tenure Completion

Three independent directors will complete their tenures shortly. Ms. Ponnari Gottipati (DIN: 09075036) will cease to be Independent Director on February 12, 2026, after completing her first term due to pre-occupational and personal reasons. Mr. Bade Srinivasa Reddy (DIN: 01384074) and Mr. Sai Roopkumar Vegunta (DIN: 05317482) will complete their second consecutive terms on March 6, 2026.

Auditor Qualifications and Regulatory Compliance

JMT & Associates expressed qualified opinions on both standalone and consolidated financial results. Key concerns include the Rs. 6,825 lakhs investment in wholly-owned subsidiary Cybermate International, Unipessoal, LDA in Portugal, which has remained non-operational for over four years with Portuguese authorities issuing cancellation notice for Certificate of Incorporation. The company incorporated new wholly-owned subsidiary Orchasp Inc in USA on December 9, 2025, and plans to transfer investments from Portuguese entity.

Recent Capital Activity

The company completed preferential allotment of 2,68,75,000 equity shares of Rs. 2 each at Rs. 3.20 per share on December 18, 2025. These shares were admitted for listing on BSE and NSE on January 28, 2026, though not reflected in share capital for the period ended December 31, 2025. The Board meeting commenced at 11:00 AM IST and concluded at 3:00 PM IST on February 10, 2026.

Orchasp Limited has provided additional clarification regarding the timing of its INDUSAYUSH electronic health records platform admission on Google Play Store, following an inquiry from the stock exchange's Listing Compliance Monitoring team. The company issued a detailed response on January 5, 2026, explaining the timeline of events surrounding the app's launch.

Platform Launch Timeline Clarification

The company clarified that the INDUSAYUSH app was admitted to Google Play Store on December 31, 2025, at 8:22 AM PST (USA time), which corresponded to 9:52 PM IST on the same day. The platform launch represents a significant milestone in Orchasp's digital healthcare initiatives.

Compliance Response and Announcement Timeline

The company addressed concerns about the timing of its regulatory announcement, explaining that the office was closed on January 1, 2026, due to New Year holidays. Orchasp noticed the platform's acceptance on Google Play Store on January 2, 2026, and made the announcement immediately thereafter.

Regulatory Compliance Details

The clarification was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company emphasized that there was no intentional delay in the announcement, stating that the disclosure was made immediately upon discovery during regular business hours.

The communication was addressed to both major stock exchanges:

• BSE Limited (Scrip Code: 532271)
• The National Stock Exchange of India Ltd (Symbol: ORCHASP)

The disclosure was signed by P. Chandra Sekhar, Managing Director & CFO (DIN: 01647212), maintaining proper corporate governance standards.

Digital Healthcare Platform Status

The INDUSAYUSH electronic health records platform is now fully operational on Google Play Store, marking Orchasp's entry into the mobile healthcare application space. The platform aims to streamline patient data management and enhance accessibility for healthcare providers, aligning with the growing trend of digital health solutions.